Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells
- PMID: 16970918
- DOI: 10.1016/j.bbrc.2006.08.152
Expression proteomics to p53 mutation reactivation with PRIMA-1 in breast cancer cells
Abstract
PRIMA-1 has emerged as a small molecule that restores the wild type function to mutant p53. To identify molecular targets that are involved in PRIMA-1-induced apoptosis, we used a proteomics approach with two-dimensional gel electrophoresis coupled with liquid chromatography-tandem mass spectrometry for protein identification. By comparing the proteome of the PRIMA-1-treated MDA-231 breast carcinoma cells with that of MCF-7 cells, we have identified seven proteins that upregulated only in MDA-231 cells as a result of PRIMA-1-induced apoptosis. The identified proteins are involved in anaerobic glycolysis and in mitochondrial intrinsic apoptosis. Treatment of MDA-231 cells with PRIMA-1 resulted in the release of mitochondrial cytochrome c as well as the activation of caspase-3, which are essential for the execution of apoptosis. We present evidence to suggest that PRIMA-1-induced apoptosis in breast cancer cells with mutated p53 function involved the expression of proteins required for the activation of mitochondrial intrinsic pathway that is glycolysis-relevant.
Similar articles
-
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?Cells. 2021 Jan 7;10(1):98. doi: 10.3390/cells10010098. Cells. 2021. PMID: 33430525 Free PMC article. Review.
-
Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.Breast Cancer Res. 2005;7(5):R765-74. doi: 10.1186/bcr1290. Epub 2005 Jul 27. Breast Cancer Res. 2005. PMID: 16168122 Free PMC article.
-
PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.Int J Oncol. 2009 Nov;35(5):1015-23. doi: 10.3892/ijo_00000416. Int J Oncol. 2009. PMID: 19787255
-
PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.Biochem Biophys Res Commun. 2007 Jan 5;352(1):203-12. doi: 10.1016/j.bbrc.2006.11.006. Epub 2006 Nov 9. Biochem Biophys Res Commun. 2007. PMID: 17113036
-
The p53 tumor suppressor: a master regulator of diverse cellular processes and therapeutic target in cancer.Biochem Biophys Res Commun. 2010 May 21;396(1):85-9. doi: 10.1016/j.bbrc.2010.02.152. Biochem Biophys Res Commun. 2010. PMID: 20494116 Review.
Cited by
-
Biomarkers in Breast Cancer: An Old Story with a New End.Genes (Basel). 2023 Jun 28;14(7):1364. doi: 10.3390/genes14071364. Genes (Basel). 2023. PMID: 37510269 Free PMC article. Review.
-
p53 and Zinc: A Malleable Relationship.Front Mol Biosci. 2022 Apr 13;9:895887. doi: 10.3389/fmolb.2022.895887. eCollection 2022. Front Mol Biosci. 2022. PMID: 35495631 Free PMC article. Review.
-
Proteomics: a strategy to understand the novel targets in protein misfolding and cancer therapy.Expert Rev Proteomics. 2010 Aug;7(4):613-23. doi: 10.1586/epr.10.70. Expert Rev Proteomics. 2010. PMID: 20653514 Free PMC article. Review.
-
PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies.Cancers (Basel). 2017 Dec 16;9(12):172. doi: 10.3390/cancers9120172. Cancers (Basel). 2017. PMID: 29258181 Free PMC article. Review.
-
Antitumor Effects of PRIMA-1 and PRIMA-1Met (APR246) in Hematological Malignancies: Still a Mutant P53-Dependent Affair?Cells. 2021 Jan 7;10(1):98. doi: 10.3390/cells10010098. Cells. 2021. PMID: 33430525 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous